Avioq HTLV-I/II
Commercial- Indications
- HTLV-I, HTLV-II
Company intelligence / Profile preview
Avioq
Durham / Research Triangle Park, North Carolina, United Statesavioq.com ↗
- Ownership
- Private
- Employees
- ~46
- Development stage
- Commercial
01
Overview
Avioq has developed FDA-approved assays for HIV and HTLV screening. Their HIV Profile™ ELISA assay provides confirmation/differentiation of antibodies to various gene products of HIV‑1 and HIV‑2. Their products are approved in the US, Canada, and Europe. They also offer contract development/manufacturing services for custom diagnostics.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein productionMonoclonal antibodyEnzyme-linked immunosorbent assay (ELISA)Diagnostic assay/device
- Industry
- Protein Biomarker Diagnostics
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Avioq.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avioq.